Suppr超能文献

[关联与相互作用:三环类抗抑郁药和选择性5-羟色胺再摄取抑制剂]

[Associations and interactions: tricyclic antidepressants and selective serotonin reuptake inhibitors].

作者信息

Eiber R, Escande M

机构信息

CMME, Hôpital Sainte-Anne, Paris.

出版信息

Encephale. 1999 Nov-Dec;25(6):584-9.

Abstract

Following the commercialization of the SSRIs clinicians described cases of drug interactions with tricyclic antidepressants among their patients. When combining tricyclic antidepressants and SSRIs clinical side effects and elevated plasma levels of tricyclics appeared. A better knowledge of the cytochrome P450 system allows to understand the mechanism of such drug interactions. The cytochrome P450 is composed of a group of isoenzymes, which are classified, into families and subfamilies on the basis of amino acid sequence homology. A number of the cytochrome genes have a genetic polymorphism responsible for poor and extensive metabolisers. The clinical importance of genetic polymorphism is highly dependent upon the therapeutic index. Thus, poor metabolisers, will experience side effects and rapid metabolisers prone to therapeutic failure. Concerning pharmacological issues SSRIs have a great affinity for at least one of the isoenzymes which accounts for drug interactions. Due to the inhibitory potential of the SSRIs drug interactions occur with tricyclics that have a narrow therapeutic index. The SSRIs do not exert the same inhibitory effect on the various isoenzymes. The inhibitory activity for an isoenzyme depends on the molecule of the SSRIs. In clinical practice, the associations between tricyclics and SSRIs should be practiced with caution. It is recommended to decrease the tricyclic dose before administering the SSRI, to start with low doses of the SSRI and to take into account the therapeutic index. Although the coadministration of tricyclics and SSRIs can produce adverse reactions it has also two main interests in clinical practice. First, the drug combination enhances clinical response to treatment. Secondly, it converts non-responders of pharmacological treatment to responders. Used with caution the association of tricyclics and SSRIs is well tolerated. However, it should be kept in mind that a single drug therapy should be tried first. These data show the complexity of drug interactions.

摘要

随着选择性5-羟色胺再摄取抑制剂(SSRI)的商业化,临床医生报告了其患者中与三环类抗抑郁药发生药物相互作用的病例。当联合使用三环类抗抑郁药和SSRI时,出现了临床副作用以及三环类药物血浆水平升高的情况。对细胞色素P450系统有更深入的了解有助于理解此类药物相互作用的机制。细胞色素P450由一组同工酶组成,这些同工酶根据氨基酸序列同源性被分为不同的家族和亚家族。许多细胞色素基因存在遗传多态性,导致代谢缓慢者和代谢快速者的出现。遗传多态性的临床重要性高度依赖于治疗指数。因此,代谢缓慢者会出现副作用,而代谢快速者则容易治疗失败。关于药理学问题,SSRI对至少一种同工酶具有很强的亲和力,这就导致了药物相互作用。由于SSRI的抑制作用,与治疗指数较窄的三环类药物会发生药物相互作用。SSRI对不同的同工酶不会产生相同的抑制作用。对一种同工酶的抑制活性取决于SSRI的分子结构。在临床实践中,三环类药物和SSRI联合使用时应谨慎。建议在使用SSRI之前降低三环类药物的剂量,从低剂量开始使用SSRI,并考虑治疗指数。虽然三环类药物和SSRI联合使用可能会产生不良反应,但在临床实践中它也有两个主要益处。首先,药物联合可增强治疗的临床反应。其次,它能将药物治疗的无反应者转变为有反应者。谨慎使用时,三环类药物和SSRI的联合使用耐受性良好。然而,应该记住首先应尝试单一药物治疗。这些数据显示了药物相互作用的复杂性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验